---
schema_version: "secwatch.filing_event.v1"
accession: "0000064803-24-000006"
form_type: "8-K"
ticker: "CVS"
cik: "0000064803"
company_name: "CVS HEALTH Corp"
filed_at: "2024-02-07T23:59:59+00:00"
generated_at: "2026-06-06T07:26:51.149320+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CVS Q4 revenue $93.8B (+11.9% YoY), adj. EPS $2.12; FY2024 adj. EPS guidance cut to $8.30

## Summary
- Q4 total revenues $93.8B (+11.9% YoY); GAAP diluted EPS $1.58, adjusted EPS $2.12.
- Full-year 2023 revs $357.8B (+10.9%), GAAP EPS $6.47, adj. EPS $8.74; ops cash flow $13.4B.
- FY2024 guidance revised: adj. EPS at least $8.30 (from $8.50), GAAP EPS at least $7.06, ops cash flow $12.0B.
- Quarterly dividend raised 10% effective Feb 1, 2024; $3.1B returned via dividends in 2023.
- Launched CVS CostVantage, Caremark TrueCost pricing models and CVS Healthspire segment for 2025.

## SEC filing metadata
- accession: 0000064803-24-000006
- form_type: 8-K
- ticker: CVS
- cik: 0000064803
- company_name: CVS HEALTH Corp
- filed_at: 2024-02-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/64803/000006480324000006/0000064803-24-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/64803/000006480324000006/cvs-20240207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000064803-24-000006
- JSON: https://secwatch.observer/filing/0000064803-24-000006.json
- Plain text: https://secwatch.observer/filing/0000064803-24-000006.txt

## Key facts
- Earnings Releases
  CVS HEALTH Corp reported three months and year ended December 31, 2023 results: revenue $93.8 billion, EPS GAAP diluted EPS of $1.58 and Adjusted EPS of $2.12. Guidance lowered.
  - Period: three months and year ended December 31, 2023
  - Revenue: $93.8 billion
  - EPS: GAAP diluted EPS of $1.58 and Adjusted EPS of $2.12
  - Guidance: lowered
  - Result: reported results
  source text: (NYSE: CVS) today announced operating results for the three months and year ended December 31, 2023. FOURTH QUARTER HIGHLIGHTS KEY FINANCIAL DATA • Total revenues increased to $93.8 billion, up 11.9% compared to prior year • GAAP diluted EPS of $1.58 and Adjusted EPS of $2.12 FULL-YEAR HIGHLIGHTS • Total revenues increased to $357.8 billion, up 10.9% compared to
  evidence_url: https://www.sec.gov/Archives/edgar/data/64803/000006480324000006/0000064803-24-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.